TheraRadar
← Back
Data updated: Mar 29, 2026

ZHEJIANG YONGTAI

CardiovascularInfectious DiseaseGastroenterology
Generics

ZHEJIANG YONGTAI is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Gastroenterology.

2019
Since
4
Drugs
-
Trials
265
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

GABAPENTIN 2026-02-24
Labeling
DOXYCYCLINE HYCLATE 2026-02-19
GABAPENTIN 2026-02-18
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-12
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 40%
2 drugs
Infectious Disease 40%
2 drugs
Gastroenterology 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

APOTHECON specialty
Infectious Disease, Cardiovascular, Gastroenterology
Pfizer big-pharma
Infectious Disease, Gastroenterology
WAYLIS THERAP big-pharma
Cardiovascular, Infectious Disease, Gastroenterology
Merck big-pharma
Infectious Disease, Cardiovascular
WARNER CHILCOTT LLC specialty
Cardiovascular, Gastroenterology, Infectious Disease